GLP-1 Medications for Weight Loss: The Complete Guide for 2026

GLP-1 receptor agonists have become the most significant development in weight loss medicine in decades. With over 30 million Americans now using these medications, they've moved from niche diabetes treatment to mainstream weight management. But the landscape is complex — multiple medications, wildly different prices, insurance battles, and a confusing regulatory environment around compounded versions.

This guide covers everything you need to know before starting a GLP-1 program in 2026, based on published clinical trial data and FDA-approved prescribing information.

How GLP-1 Medications Actually Work

GLP-1 receptor agonists are synthetic versions of a gut hormone called glucagon-like peptide-1 (GLP-1) that your body naturally produces after eating. They work through three distinct mechanisms:

• •Appetite suppression: They act on GLP-1 receptors in the hypothalamus — your brain's satiety center — reducing hunger signals. They also lower ghrelin (the "hunger hormone") and increase fullness hormones like peptide YY.
• •Delayed gastric emptying: They slow how quickly food leaves your stomach, keeping you feeling full longer after meals.
• •Glucose regulation: They stimulate insulin release and suppress glucagon from the pancreas, which is why they were originally developed for Type 2 diabetes.

Tirzepatide (sold as Zepbound and Mounjaro) takes this further — it's a dual GIP/GLP-1 receptor agonist, activating two different incretin receptors simultaneously. This dual mechanism may explain why tirzepatide consistently shows higher weight loss numbers in clinical trials.

FDA-Approved GLP-1 Medications for Weight Loss

As of early 2026, the following medications are FDA-approved specifically for chronic weight management:

Ozempic and Mounjaro are FDA-approved only for Type 2 diabetes, not weight loss. However, doctors can and do prescribe them off-label for weight management. If your provider prescribes Ozempic instead of Wegovy, this is legal but your insurance may not cover it for weight loss.

What the Clinical Trials Show

The weight loss numbers from major clinical trials are significant. These are averages from large, placebo-controlled studies published in peer-reviewed journals like the New England Journal of Medicine.

In the STEP 1 trial, about 86% of participants on semaglutide 2.4mg achieved at least 5% weight loss, and roughly 51-64% lost 15% or more. In SURMOUNT-1, 96% of participants on the 15mg tirzepatide dose achieved at least 5% weight loss, and 36% lost more than 25% of their body weight.

The head-to-head SURMOUNT-5 trial (published May 2025 in NEJM) showed tirzepatide produced significantly greater weight loss than semaglutide at maximum doses — 20.2% vs 13.7%. Tirzepatide also had a lower rate of GI-related discontinuation (2.7% vs 5.6%).

Side Effects: What to Expect

GI side effects are the most common issue. From the Wegovy prescribing information and STEP trials:

The key insight: 98.1% of GI side effects were mild-to-moderate. Only 4.1% of Wegovy patients reported severe GI reactions. Side effects are worst during dose escalation (the first few weeks at each new dose level) and generally decrease over time. Both medications use gradual dose-titration schedules specifically to minimize these effects.

Who Qualifies for GLP-1 Medications

The FDA-approved eligibility criteria for GLP-1 weight loss medications:

• •BMI of 30 or higher (obesity), OR
• •BMI of 27 or higher (overweight) with at least one weight-related health condition

Qualifying comorbidities include Type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, sleep apnea, non-alcoholic fatty liver disease (NAFLD), and PCOS, among others.

Wegovy is also approved for patients aged 12 and older with obesity. Insurance companies may apply stricter criteria — some require a BMI of 35+, documented failed diet/exercise attempts, or prior authorization.

Choosing a Provider

Most GLP-1 prescriptions in 2026 come through telehealth platforms. When evaluating providers, consider:

• •Medication options: Do they offer both brand-name and compounded? Brand-only? Only compounded?
• •Clinical support: Is there ongoing physician oversight, or just an initial consultation?
• •Insurance: Do they accept your insurance, or is it cash-pay only?
• •Total cost: Monthly medication cost plus any consultation, lab work, or membership fees.
• •Dose titration: Do they follow standard dose escalation schedules?

We independently evaluate and rank 30+ telehealth GLP-1 providers on our homepage. Check our rankings or take our quiz to find the best match for your budget and preferences.